Ocean Biomedical (NASDAQ: OCEA) has been granted a European patent for its breakthrough Idiopathic Pulmonary Fibrosis discovery. The announcement comes after the European Patent Office granted Dr. Jack A. Elias, MD, Ocean Biomedical's Scientific Co-founder, a patent for Methods and Compositions relating to the treatment of fibrosis using Ocean’s anti-Chitinase 1 small molecule candidate (“Small Molecule X”). This new approach has potential in treating IPF and other fibrotic diseases such as Scleroderma, Nonalcoholic Steatohepatitis (NASH), Hermansky-Pudlak syndrome (HPS), and Alcoholic Liver Disease.
The patent notice extends global coverage for this discovery that has shown an 85%–90% reduction in collagen accumulation in four “gold standard” IPF and HPS pulmonary fibrosis animal models. This new treatment approach is anticipated to be well-tolerated based on data from original clinical studies and recent EPA data.
Fibrosis is a condition that affects most organs and tissues, causing “runaway scarring,” which is